The Investor Relations website contains information about MacroGenics, Inc.'s business for stockholders, potential investors, and financial analysts.
04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based ...
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
(MGNX) CEO Scott Koenig on Q1 2022 Results - Earnings Call Transcript · SA TranscriptsTue, May 03, 2022. MacroGenics (MGNX) Investor Presentation - Slideshow.
Get the latest insights on MacroGenics, Inc. Common Stock (MGNX) with press releases and corporate news to help you in your trading and investing decisions.
Mar 1, 2024 · Leerink Partners 2024 Global Biopharma Conference (Miami). Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, March 12, ...
Feb 27, 2024 · ... Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be ...
Nov 2, 2023 · ... Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of ...
Jul 31, 2023 · ... Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be ...
Welcome to our dedicated news page for Macrogenics (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics.